abagovomab

10/01/2014 - "To determine whether abagovomab induces protective immune responses in ovarian cancer patients in first clinical remission. "
03/01/2011 - "Abagovomab for ovarian cancer."
02/01/2011 - "Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer."
03/13/2009 - "Abagovomab is a monoclonal, anti-idiotypic antibody developed as an immunovaccine for the treatment of ovarian cancer. "
12/01/2008 - "Anti-idiotypic antibody abagovomab in advanced ovarian cancer."

07/01/2007 - "Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer."
09/15/2006 - "Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer."
01/01/2010 - "Because of the central role of regulatory T cells (Tregs) in tumor immunology, we analyzed the frequency and suppressive activity of CD25(+)FoxP3(+) Tregs in 16 patients treated with abagovomab. "
02/01/2011 - "Abagovomab is a murine monoclonal anti-idiotypic antibody (molecular weight: 165-175 kDa) that functionally imitates the tumor-associated antigen, CA-125. "
10/01/2014 - "The present analysis is a substudy of monoclonal antibody immunotherapy for malignancies of the ovary by subcutaneous abagovomab trial (NCT00418574). "

10/01/2014 - "Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial."
04/20/2013 - "Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study."
02/01/1997 - "We used ACA125 as a surrogate for the tumor-associated antigen CA125 for vaccine therapy of 16 patients with advanced epithelial ovarian cancer or recurrences. "

03/01/2004 - "Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II)."
02/01/1999 - "In a first clinical trial, 45 patients with advanced ovarian carcinoma and recurrences were treated with the murine monoclonal anti-idiotypic antibody (Ab2) designated ACA125 for active immunotherapy. "
05/01/2001 - "Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. "
05/01/2001 - "Wagner et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. "
05/01/2001 - "The aim of the present study was to assess whether the induction of specific immune responses by vaccination with the murine monoclonal anti-idiotypic antibody ACA125, which imitates the tumor-associated antigen CA125, has a positive influence on the survival of patients with recurrent ovarian carcinoma. "

01/01/1999 - "[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)]."